Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genix PharmaceuticalsGENPF EV-to-EBITDA is -16.40 as of Aug. 11, 2026. The stock has 3 warning signs investors should review. Among 736 Drug Manufacturers companies, Genix Pharmaceuticals ranks worse than 135869.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genix Pharmaceuticals's enterprise value is $1.48 Mil.
Genix Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-0.09 Mil. Therefore, Genix Pharmaceuticals's EV-to-EBITDA for today is -16.40.
The historical rank and industry rank for Genix Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
GENPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -121.68 Med: -14.44 Max: 150.03
Current: -16.49
During the past 13 years, the highest EV-to-EBITDA of Genix Pharmaceuticals was 150.03. The lowest was -121.68. And the median was -14.44.
GENPF's EV-to-EBITDA is ranked worse than 100% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.185
vs GENPF: -16.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genix Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Genix Pharmaceuticals's share price for today is $0.0138.
Genix Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Genix Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Genix Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genix Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genix Pharmaceuticals's EV-to-EBITDA falls into.
Genix Pharmaceuticals's current Enterprise Value is $1.48 Mil.
Genix Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genix Pharmaceuticals (GENPF) has a EV-to-EBITDA of -16.40 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genix Pharmaceuticals. According to the industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 736 companies in the Drug Manufacturers industry.
Is Genix Pharmaceuticals' EV-to-EBITDA too high?
Genix Pharmaceuticals' current EV-to-EBITDA is -16.40. Based on the distribution chart, Genix Pharmaceuticals ranks #999999 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Genix Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Genix Pharmaceuticals ranks #999999 out of 736 companies for EV-to-EBITDA. This places Genix Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.19, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genix Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current EV-to-EBITDA is -16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current EV-to-EBITDA of -16.40. The current EV-to-EBITDA is -16.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current EV-to-EBITDA is -16.40 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENPF has been successfully added to your 
